

Protective Peptides Neurotoxin of C. Botulinum

Field of the Invention:

This invention relates to immunization against toxic effect of neurotoxins of Clostridium botulinum. Protective epitopes of the heavy chain of the neurotoxin of C. botulinum have been discovered. The invention also relates to preparation of protective immunotoxins of C. botulinum.

Background of the Invention:

Botulinum neurotoxin (BoNT) is one of the most potent toxins known to man. Ingestion or inhalation of toxin inhibits neurotransmitter release from synaptic vesicles, resulting in neuroparalysis and death. Seven serologically distinct forms of neurotoxin are produced by Clostridium botulinum. The toxin is synthesized as a 150 kDa precursor that is proteolytically nicked into two subunits. The light (L) chain, associated with the toxicity of BoNT, must be internalized in the cell in order to inhibit neurotransmitter release. It is linked by a disulfide bond to the heavy (H) chain, which mediates binding of the toxin to receptors located on the surface of the nerve cell. Although the heavy chain is required for BoNT to productively bind and enter the target cell, it is not toxic by itself.

The current pentavalent toxoid vaccine for botulism is composed of formalin-inactivated holotoxin. Although effective, this vaccine is difficult to manufacture. Furthermore, extensive treatment with formalin is required to inactivate the toxin. Prolonged treatment with formalin can affect the immunogenicity of protein antigens, and this may explain why certain lots of toxoid have been poorly immunogenic in the past.

There are several approaches that can be used to construct a new vaccine. One approach would be to express a non-toxicogenic mutant of BoNT/A, as has already been done for other toxins. The advantage of this approach is that the immune response elicited by the modified protein would most closely approximate the response elicited by the native toxin, because almost all of the

native protein structure would still be intact. However, high level expression of the C fragment of tetanus toxin (TeTx) could not be achieved in E. coli when the native clostridial gene sequence was used. Based on this information, expression of BoNT might be predicted to be difficult, as well. Another approach is to construct a synthetic peptide-based vaccine. The advantage of this approach is that large quantities of synthetic peptide can be easily manufactured for use in a vaccine. However, studies with MAbs have indicated that many of the neutralizing epitopes located on BoNT are conformationally sensitive. This suggests that a peptide-based vaccine may not necessarily be able to induce neutralizing antibody responses due to its lack of conformational epitopes. A genetically engineered vaccine for botulism would eliminate many problems, since it could be expressed in a recombinant host at high levels and would not require treatment with formalin before incorporation into a vaccine.

Recent developments have made the construction of a genetically engineered BoNT vaccine possible. The gene for BoNT serotype A (BoNT/A) has been cloned and sequenced (Binz, et al., J. Biol. Chem. 265:9153-9158.(1990), and the minimum length of the light chain needed to retain neurotoxicity has been defined (Kurazono, et al., J. Biol. Chem. 267:14721-14729 (1992)). While construction of such a vaccine is feasible, there has not been a systematic attempt to identify the domain(s) of BoNT/A that would be required to elicit protective immunity. Immunization with a fragment corresponding to the C-terminal half of the heavy chain (H_c) has been shown to stimulate protective immunity, but more definitive identification of sequences that elicit protective immune response had not previously been described. Monoclonal antibodies directed against either light chain or heavy chain determinants had been shown to provide some passive protection to mice against a lethal exposure to BoNT, indicating that protective epitopes may exist on either chain. However, many of these epitopes appear to be conformationally sensitive, which suggests

that mapping their location by using synthetic peptides may be unproductive due to their lack of tertiary structure.

Summary of the Invention:

It is the purposes of this invention to provide methods for developing vaccines to protect from neurotoxins of C. botulinum. The methods used to identify specific sequences consisted of amplifying and cloning overlapping segments of the BoNT/A gene. These segments are then expressed in suitable vectors such as E. coli to produce truncated BoNT/A proteins of about 15-30 kDa in size. The truncated proteins are purified by appropriate methods such as SDS-PAGE. The invention is exemplified using two particularly protective regions from the heavy chain of the type A C. botulinum toxin. The peptides giving rise to protective antibodies may be fused to other peptides that act as adjuvants to increase antigenicity. Such fusion proteins may be produced by recombinant technology using plasmids containing hybrid genes for expression of the desired fusion proteins.

Detailed Description of the Invention:

It is the purpose of this invention to identify and provide immunogenic polypeptides which give rise to protective antibodies against botulism. Compositions containing the subject polypeptides in pharmaceutically acceptable carriers are useful as vaccines and as diagnostic agents to identify protective antibodies.

The location of protective domains was identified, and those domains were produced by expressing fragments of BoNT/A in E. coli and then evaluating each for its protective efficacy. Using this approach, fragments of the BoNT/A gene were expressed that were of sufficient size to still possess some tertiary conformation, but that would greatly reduce the amount of the toxin utilized. By overlapping the regions of the BoNT/A protein being expressed, it was possible to minimize the possibility that a locally encoded epitope was accidentally interrupted. The advantage of this approach is that the fragments were sufficiently small to be nontoxic. However, it is possible that not all

protective determinants may have been encoded by these fragments.

It was possible to express fragments of the BoNT/A gene at high levels in E. coli by using an inducible T7 expression system. It was not predictable that, in contrast to some of the problems encountered with expression of the C fragment of tetanus toxin (TeTx), this could be done for purposes of making a protective vaccine against botulism. Some difficulty encountered ~~which~~ was related to the fact that clostridial toxin is encoded by codons that are rarely used by E. coli. Unexpectedly, this problem with the DNA sequence naturally encoded by Clostridium did not present the barrier that might have been expected. The possibility for expression of these proteins may be due to the size of the BoNT/A proteins encoded. The TeTx proteins being expressed in E. coli were two to three times larger than the BoNT/A proteins expressed as disclosed herein. The smaller size of the BoNT/A transcripts may have permitted E. coli to translate them more efficiently. However, the truncated BoNT/A proteins were expressed primarily in the form of insoluble inclusion bodies. Insertion of the BoNT/A gene fragments into the plasmid vector pMTD74 resulted in expression of a BoNT/A protein fused to the A2 peptide of cholera toxin (CtxA2) at its C-terminus. These fragments were fused to CtxA2 to associate noncovalently with the B subunit of cholera toxin (CtxB). Fusion of antigens to CtxB was shown to improve their immunogenicity when administered by mucosal routes of immunization (Dertzbaugh, et al., Infect. Immun. 61:48-55 (1993)). Hence, CtxB is used as a delivery system with these fragments of BoNT/A as part of a mucosally administered vaccine for botulism.

The ability of the BoNT/A fragments to induce an antibody response was affected by the antigen preparation used for immunization. Effective production of antibody to BoNT/A was inadequate when the crude lysates were used for immunization, even though they contained relatively large amounts of BoNT/A-specific protein. For this reason, immunization was performed again with highly enriched preparations of the BoNT/A proteins.

Unlike the crude form of the antigen, the purified form was able to elicit BoNT/A-specific antibody whilst being well tolerated by the animals. The poor immunogenicity of the crude lysates may have been due to saturation of the antigen-presenting cells with other antigens present. It is possible that by purifying the BoNT/A proteins, other immunodominant antigens were removed which could have been competing for uptake and presentation to lymphocytes by the antigen-presenting cells.

Preparative SDS-PAGE was used to purify the BoNT/A fragments for several reasons. First, most of the BoNT/A protein present in the lysates were in the form of inclusion bodies that had to be solubilized before purification. SDS easily solubilized the BoNT/A proteins. Second, this method can be used to purify all of the fragments, regardless of their size or composition. Furthermore, the size range of the BoNT/A proteins permitted them to be separated from most of the other proteins present in the lysates. One potential disadvantage of using such a denaturing method is that the purified BoNT/A proteins may not have completely resumed their native conformation, resulting in the loss of some epitopes. The BoNT/A proteins should have been able to refold when the SDS was removed from the antigen preparations before immunization.

Hybrid gene fusion proteins may also be produced to increase protective immune response. For example, DNA sequences which encode desired antigenic polypeptides may be fused to DNA sequences which encode non-toxic peptides of other organisms such as cholera. U.S. Patent 5,268,276 to Holmgren, et al., which is incorporated herein in its entirety by reference, discloses a means of producing an appropriate fusion gene to produce fusion proteins containing the immunogenic peptides of botulism.

Both BoNT peptides and fusion proteins containing BoNT amino acid sequences may be administered by mouth. Antigenic fusion proteins containing sequences of cholera subunits are useful for administration orally or to the mucosa (for example intranasally). The fusion proteins may be lyophilized and inhaled from a

vial for administration.

Compositions containing the BoNT peptides in pharmaceutical-
ly acceptable carriers may also be administered parenterally.
Preferred parenteral routes include intracutaneous or subcutane-
ous or intramuscular injection. Any of the compositions may
contain, additionally, adjuvants such as alum or Freund's
adjuvant. While the invention has been exemplified using the
peptides of C. botulinum, serotype A, analogous polypeptides
sequences of other serotypes can be made in the manner described
herein. A cocktail of polypeptides from various serotypes may be
administered to provide broad protection against toxins of C.
botulinum serotypes.

Materials and Methods:

Construction of the BoNT/A gene fragments. The polymerase
chain reaction (PCR) was used to amplify and clone overlapping
fragments of the BoNT/A gene. Primers used to amplify each
fragment are listed in Table 1. The primers were designed to
include unique flanking restriction sites on the 5' and 3' ends
of each amplified fragment in order to permit its insertion into
the expression vector. Plasmids pCBA2, pCBA3, and pCBA4 encoding
large overlapping regions of the BoNT/A gene and flanking DNA
were used as template DNA (Thompson, et al., Eur. J. Biochem.
73-81 (1990)). Amplification was performed using Vent DNA
polymerase (New England Biolabs, Beverly, Mass.). The reaction
mixture was prepared according to the manufacturer's directions,
and consisted of 100 ng/ μ l forward primer, 100 ng/ μ l reverse
primer, and 10 ng/ μ l template. Each reaction was subjected to 25
cycles of amplification in a DNA thermocycler according to the
following parameters: melting temperature, 94°C for 1 min;
annealing temperature, 45°C for 1 min; extension temperature,
72°C for 1 min. The amplified DNA was digested with the
appropriate restriction enzymes and then was ligated into the
expression vector pMTD74.

TABLE 1. PCR primers

| n.t. ^a | Direction ^c | Sequence |
|--|--|----------|
| 367-741 L ₄₋₁₂₈ ^b | F: 5'-ATATGGAATTCGTTAATAACAATTTAATTATAAAGATCC-3' R: 5'-AGTATCGTCGACTTTTAATTCGTATCTATTGTACTTCCACC-3' | |
| 732-1170 L _{126-271b} | F: 5'-GATACAGAATTCAAAGTTATTGATACTAATAG-3' R: 5'-CTTTGCGTCGACTCCCCCAATGTTCTAAGTTCC-3 | |
| 1126-1750 L _{257-465b} | F: 5'-GGGTTAGAATTCAGCTTTGAGGAACCTTAGAACATTTGGG-3' R: 5'-AGGACTGTCGACCAAGTCCCAATTATTAACTTTGATTGATAAATC3' | |
| 1720-2340 H _{455-661b} | F: 5'-TTAAATGAATTCCTCAATCAAAGTTAATAATTGGGAC-3' R: 5'-CTCTGGGTCGACTTCTAACAGAATAACAGCTCC-3' | |
| 2150-2780 H _{630-808b} | F: 5'-GAAGTAAGAGCTCTGGATAAAATTGCGGATATAAC-3' R: 5'-TAACCGGTCGACACCATAAGGGATCATAGAG-3' | |
| 2695-3175 H _{780-939b} | F: 5'-GCTATGATTAAATATAAATAAAATTTTGAATCAATGC-3' R: 5'-AGTACTAAGCTTTTCATACATACTATTATATACAATAGC-3' | |
| 3100-3530 H _{915-1059b} | F: 5'-AAAAATAGAGCTCAATTATTTAATTTAGAAAGTAG-3' R: 5'-ACCATCGTCGACAAACATTATATTATTACTAGC-3' | |
| 3301-3726 H _{982-1123b} | F: 5'-TATGGTGAATTCATCTGGACTTTACAGGATACTCAGG-3' R: 5'-ATTTACGTCGACATATTTATTGGATC-3' | |
| 3590-4020 H _{1078-1220b} | F: 5'-GATAAGGAATTCAAATGAAAAAGAAATCAAAG-3' R: 5'-CTTCATGTCGACTACTTGACTTAGATTTC-3' | |
| 3806-4223 H _{1150-1289b} | F: 5'-AACATTGAATTCAAATCAAGTTGTATAGGGGG-3' R: 5'-TCCATCGTCGACAGGAATAAATCCCATTGAGCTACC-3' | |

^a Nucleotide sequence number designation based on EMBL/Genbank™ accession file X52066.

^b Amino acid residue number of the light (L) chain and the heavy (H) chain.

^c F, forward primer; R, reverse primer.

Bacterial strains and plasmids. Plasmids constructed are listed in Table 2. All plasmids were transformed by the CaCl_2 -heat shock method (See Morrison, D. A., J. Bacteriol. 132:349-351 (1977)) into E. coli strain HMS174(DE3) (Campbell, et al., Proc. Natl. Acad. Sci., U.S.A., 75:2276-2280 (1978)). Bacterial strains were grown at 37°C in M-9 medium in accord with the methods of Miller (Miller, J. H., Experiments in Molecular Genetics, Cold Spring Harbor Laboratory, Cold Spring Harbor (1972)) supplemented with 10 g of Casamino Acids (Difco Laboratories, Ann Arbor, Mich.) per liter, 20 µg of leucine per ml, 20 µg of proline per ml, 2 µg of thiamine per ml, 50 µg of ampicillin per ml, and 25 µg of rifampicin per ml. Plasmid pMTD74 was used to express the BoNT/A fragments in E. coli. It was derived from the T7 translation vector pET-8c (Studier, et al., Methods in enzymology, Academic Press, New York (1990)) and has a multiple cloning site encoding unique restriction sites. This plasmid was used to express fragments of the BoNT/A gene in E. coli. It encodes a gene for ampicillin (Ap) resistance and a ColE1 origin of replication (ORI). Transcription is initiated from the T7 promoter and is terminated by the T ϕ transcriptional terminator (t.t.). Proper in-frame insertion of DNA within the multiple cloning site (MCS) results in expression of protein fused to the A2 peptide of cholera toxin (CtxA2). (Lockman, et al., J. Biol. Chem. 258:13722-13726 (1983)). The MCS contains several unique restriction sites, and is shown in more detail below the plasmid map. Translation is initiated by the Shine-Delgarno (S.D.) sequence located upstream of the initiator methionine encoded by the NcoI site. Transformation of this plasmid into the lysogenic E. coli strain HMS174(DE3) permits inducible expression of protein from the T7 promoter. T7 RNA polymerase is required for initiation of transcription from the T7 promoter, and this protein is inducibly expressed in HMS174(DE3) by using isopropyl-beta-D-thiogalactopyranoside (IPTG).

TABLE 2. Bacterial strains and plasmids

| <u>E. coli</u> Strain | Plasmid | Comments | Refer- ences |
|--------------------------|---------|---|-----------------|
| | pMTD74 | | |
| HMS174 | | F' <u>hsdR</u> (<u>r_K</u> <u>m_K</u>) <u>recA</u> <u>rif^R</u> | Campbell* |
| HMS174 (DE3) | | T7 expression host | Studier** |
| MTD103 | pMTD89 | BoNT/A L ₄₋₁₂₈ | |
| MTD143 | pMTD143 | BoNT/A H ₄₅₅₋₆₆₁ | |
| MTD145 | pMTD130 | BoNT/A H ₇₈₀₋₉₃₉ | |
| MTD150 | pMTD74 | HMS174 (DE3) host for background control | |
| MTD164 | pMTD162 | BoNT/A H ₉₈₂₋₁₁₂₃ | |
| MTD165 | pMTD163 | BoNT/A H ₁₁₅₀₋₁₂₈₉ | |
| MTD191 | pMTD186 | BoNT/A L ₁₂₆₋₂₇₁ | |
| MTD193 | pMTD188 | BoNT/A H ₁₀₇₈₋₁₂₂₀ | |
| MTD196 | pMTD187 | BoNT/A L ₂₅₇₋₄₆₅ | |
| MTD203 | pMTD195 | BoNT/A H ₉₁₅₋₁₀₅₉ | |
| MTD210 | pMTD148 | BoNT/A H ₆₃₀₋₈₀₈ | |

* Campbell, et al., Proc. Natl. Acad. Sci., U.S.A. 75:2276-2280 (1994)

** Studier, et al., Methods in Enzymology, Academic Press, New York (1990)

Analysis of protein expression. Transformants were screened for protein expression by immunoblotting analysis. Individual colonies were grown at 37°C in 2 ml of M-9 medium to an optical density of 0.8-1.0 at 660 nm. Expression was induced by adding IPTG to a concentration of 0.25 mM. After induction, cultures

5 were incubated at 37°C for 2 h before harvesting. The cells were
pelleted in a microfuge tube and resuspended in 100 µl of sample
loading buffer containing 1% sodium dodecyl sulfate (SDS) and 0.2
M 2-mercaptoethanol. The samples were boiled for 5 min and then
separated by discontinuous SDS-polyacrylamide gel electrophoresis
(PAGE) (Lammeli, U. K., Nature **227**:680-685 (1970)). The proteins
were transferred to nitrocellulose sheets using a semi-dry
electroblotter (Integrated Separation Systems, Hyde Park, Mass.)
10 and then stained for the presence of BoNT/A-specific protein
using horse antiserum to BoNT/A. Strain MTD150 was prepared as
described above and used as a background control. Purified
BoNT/A (Sigma, St. Louis, Mo.) was included in each gel as a
positive control.

15 **Cell fractionation.** Bacterial strains encoding the
truncated BoNT/A proteins were grown in M-9 medium and were
induced to express protein as described above. Cells were
pelleted by centrifugation at 3,000 x g for 10 min. The pellet
was suspended in lysis buffer containing 1 mg/ml lysozyme, 50 mM
Tris, 50 mM EDTA, and 20% sucrose (pH 8.0) and was incubated at
20 37°C for 30 min. To ensure complete lysis, the cell suspension
was subjected to two cycles of rapid freeze-thaw. MgSO₄ was
added to the lysate to a concentration of 20 mM, DNase (Sigma)
and RNase (Sigma) were added to a concentration of 0.01 mg/ml
each, and then the lysate was incubated at 37°C for 30 min. The
25 lysate was clarified by centrifugation at 3,000 x g for 10 min.
The clarified lysate was centrifuged at 20,000 x g for 30 min at
4°C and the resulting pellet was dissolved in sample loading
buffer. The sample was boiled for 5 min and stored at -20°C
before use.

30 **Purification of BoNT/A proteins.** The truncated BoNT/A
proteins were purified by preparative SDS-PAGE with a Model 491
Prep Cell (Bio-Rad, Richmond, Ca.). The percentage of acrylamide
used in the resolving gel was adjusted to maximize the separation
of the protein of interest. Separation was typically performed
35 at 12 watts constant power with a 37-mm diameter tube gel. The

length of the stacking and resolving gels were 2 cm and 10 cm, respectively. The eluate was collected at a flow rate of 0.75 ml/min as 4-ml fractions. Aliquots of the fractions were separated by analytical SDS-PAGE and stained with Coomassie blue to visualize total protein. In some cases, a duplicate gel was transferred to nitrocellulose and analyzed for immunoreactivity to polyclonal horse antiserum to BoNT/A. Fractions containing truncated BoNT/A protein were pooled and concentrated by ultrafiltration (Amicon, Danvers, Mass.). The concentrated protein was passed through a column containing Extracti-Gel™ D resin (Pierce, Rockford, Ill.) to remove any remaining SDS. The protein was subjected to extensive diafiltration in buffer containing 120 mM NaCl, 2.7 mM KCl, 10 mM phosphate buffer (pH 7.4), 20% glycerol (v/v), and 5 mM EDTA. Each protein preparation was examined by Coomassie staining and immunoblotting analysis for its composition and for the presence of BoNT/A-specific protein. Protein concentrations were determined by the BCA assay (Pierce). The protein preparations were aliquoted and stored at -70°C before use.

Immunization and challenge. The protocol used in this study was approved by the USAMRIID Institutional Animal Care and Use Committee. Female CB6F1 mice (Jackson Laboratory, Bar Harbor, Maine), 4-6 weeks old, were provided food and water ad libitum. The mice were immunized with 10 µg of BoNT/A-specific protein suspended in adjuvant emulsion (Ribi Immunochem, Hamilton, Mont.). Some mice were immunized with saline emulsified in adjuvant for use as negative controls. For comparison, some mice were immunized with pentavalent toxoid. The mice were immunized i.p. four times at 2-week intervals. One week after the last immunization, the mice were bled and the serum was analyzed by immunoblot for the presence of chain-specific antibody. Two weeks after the last immunization, each mouse was challenged i.p. with 2 lethal doses of BoNT/A (2 MIPLD₅₀). Four days after challenge, the mice were scored for survivors.

Immunoblotting analysis. BoNT/A was separated by SDS-PAGE